Latest News

24th January, 2019

OncoImmunity signs a collaboration agreement with a leading European vaccine development company

OncoImmunity announced today the signing of a collaboration agreement with a European cancer vaccine company. The companies will cooperate to preclinically access the predictive capabilities of OncoImmunity's artificial intelligence platform called the ImmuneProfiler™ to identify immunogenic neoantigens in sarcoma.

The newly signed collaboration agreement adds to a growing list of European, North American and Asian companies and organisations that are using the ImmuneProfiler™ platform to identify optimal neoantigen targets.

Please enable your browser to accept cookies and refresh this page to enjoy the best experience from this website and to dismiss this message.
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies.OK